收藏切换
Preparation and anti-tumor activity of a novel antibody-drug conjugate 607-LDM
收藏切换
PDF
Qun YU1, Jia-lu YUAN2, 3, Xiao-tian ZHAI1, Jian MA2, 3, Qing-fang MIAO*, 1, Yong-su ZHEN1
Acta Pharmaceutica Sinica | 2021, 56(2) : 496 - 502
Less
收藏切换
Acta Pharmaceutica Sinica | 2021, 56(2): 496-502
Original Articles
Preparation and anti-tumor activity of a novel antibody-drug conjugate 607-LDM
Full
Qun YU1, Jia-lu YUAN2, 3, Xiao-tian ZHAI1, Jian MA2, 3, Qing-fang MIAO*, 1, Yong-su ZHEN1
Affiliations
  • 1. NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing 100050, China
  • 2. National Engineering Research Center of Antibody Medicine, Shanghai 201203, China
  • 3. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Shanghai 201203, China
Published: 2021-02-12 doi: 10.16438/j.0513-4870.2020-1225
Outline
收藏切换

Antibody-drug conjugates(ADCs) are one of the most important classes of anticancer therapeutics.Human epidermal growth factor receptor-2(HER2), which is highly expressed in many types of aggressive cancers including breast and ovarian cancer, has been approved as an ideal target for ADCs. Lidamycin(LDM), developed by Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, is an enediyne-containing antibiotic with potent anti-tumor activity. LDM is a promising payload for ADCs. In the present research, using a special site-directed conjugating technology, we made a novel ADC(607-LDM) with a drug-to-antibody ratio(DAR) of 2 and composed of the anti-HER2 antibody 607 and LDM. The new ADC exhibited potent antitumor activity against human ovarian cancer SKOV3 and breast cancer BT-474 cells. It also induced apoptosis and G2/M arrest.In nude mice with SKOV3 xenografts and a tumor volume of 150-200 mm3, a single intravenous injection 607-LDM at 1 mg·kg-1 induced tumor growth inhibition of 72.4%, which was significant compared to either LDM(50.6%) or antibody(30.2%) treatment alone, or both in combination(50.1%, P < 0.05). All animal experiments were performed in accord with National Regulations and approved by the Animal Experiments Ethical Committee of College of Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences. The novel ADC designed in this study, 607-LDM, is a promising candidate for the treatment of HER2-positive cancers.

antibody-drug conjugate  /  human epidermal growth factor receptor 2  /  lidamycin  /  ovarian cancer  /  breast cancer  /  anti-tumor activity
Qun YU, Jia-lu YUAN, Xiao-tian ZHAI, Jian MA, Qing-fang MIAO, Yong-su ZHEN. Preparation and anti-tumor activity of a novel antibody-drug conjugate 607-LDM[J]. Acta Pharmaceutica Sinica, 2021 , 56 (2) : 496 -502 . DOI: 10.16438/j.0513-4870.2020-1225
Year 2021 volume 56 Issue 2
PDF
168
66
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2020-1225
  • Receive Date:2020-07-21
  • Online Date:2025-12-18
  • Published:2021-02-12
Article Data
Affiliations
History
  • Received:2020-07-21
  • Revised:2020-08-06
Funding
Affiliations
    1. NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing 100050, China
    2. National Engineering Research Center of Antibody Medicine, Shanghai 201203, China
    3. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Shanghai 201203, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2020-1225
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT